VIENNA, Oct. 16, 2012 /CNW/ -
The Investigating Manic Phases And Current Trends in Bipolar (IMPACT) study, which was designed to investigate the effects of periods of mania in people diagnosed with bipolar I disorder, also found for over three-quarters of respondents,bipolar I disorder had decreased their own expectations of success in life.
For media outside China, Japan and USA only.
Lundbeck today announced results from an international study of people living with bipolar I disorder, which found a significant proportion of patients experience symptoms of depression during an episode of mania. The IMPACT of Bipolar study (Investigating Manic Phases And Current Trends) found 64% of people reported experiencing feeling depressed during a manic episode.Bipolar I disorder, a subset of bipolar disorder, is a chronic, episodic illness characterised by mania, depression, or a combination of both.
"The results of the global IMPACT of Bipolar study show depression is a significant factor during mania for a considerable number of bipolar I patients," said Professor Eduard Vieta, Director of the Bipolar Disorders Program Hospital Clinic at the University of Barcelona. "Depressive symptoms can have a marked impact on patients with bipolar I disorder. This impact is compounded when the depression also occurs during an episode of mania. Continued research is critical to improve approaches to effective management."
Bipolar I disorder was also found to have an impact on relationships and the work lives of respondents with 45% reporting they had lost a job and 38% were separated or divorced as a result of the disorder. Over three-quarters (76%) reported that bipolar I disorder had decreased their own expectations of success in life.
"Bipolar I disorder can have a dramatic effect on the lives of those living with the disorder and their family and friends," said Paul Arteel, Executive Director of the Global Alliance of Mental Illness Advocacy Networks (GAMIAN) Europe. "The IMPACT of Bipolar Study found that a significant number of participants become more pessimistic about their future after diagnosis which can have a dramatic affect on their sense of wellbeing."
The IMPACT of Bipolar Study involved 700 respondents in Australia, Canada, Italy, France, Germany, Spain and the UK, aged 18-65 who had been diagnosed with bipolar I disorder for 12 months or more. The study primarily investigated the effects of periods of mania in those diagnosed with bipolar I disorder.
Bipolar disorder affects 30 million people worldwide including over four million people in Europe. It is the sixth leading cause of disability worldwide. People with bipolar disorder are part of a medically-burdened population that often experience multiple complications.
About bipolar I disorder
Bipolar disorder (also known as manic-depressive disorder) is a chronic, episodic illness so named because sufferers alternate between two poles of extreme moods - mania and depression.Bipolar I disorder is characterised by mania (episodes of elevated moods, extreme irritability, decreased sleep and increased energy), depression (overwhelming feelings of sadness, suicidal thoughts), or a combination of both.
About IMPACT of Bipolar Study
The Investigating Manic Phases And Current Trends (IMPACT) study primarily investigated the effects of periods of mania in people diagnosed with bipolar I disorder. The study involved 700 respondents in Australia, Canada, Italy, France, Germany, Spain and the UK aged 18-65 who had been diagnosed with bipolar I disorder for 12 months or more. Respondents participated in an online questionnaire between March and August 2012. The study was commissioned by Lundbeck Ltd and conducted in the UK, Spain, France, Italy, Germany, Canada and Australia by Phoenix Healthcare International. Further results of the IMPACT of Bipolar Study are available online at http://www.impactofbipolar.com/
About Phoenix Healthcare International
Phoenix Healthcare International provides research, marketing and consulting services to the world's leading Pharma, Biotech, Medical Device, Diagnostic and Healthcare Organisations. Phoenix Healthcare International is part of Phoenix Marketing International, founded in 1999 and now the 30th largest market research firm in the most recent Honomichl report.
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, please visit http://www.lundbeck.com/.
1 . IMPACT of Bipolar Study 2012 (Data on file)
2 . World Health Organization. Disease incidence, prevalence and disability. Available at:http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part3.pdf. Accessed August 24, 2012.
3 . Kleinman, L et al. Costs of bipolar disorder. Pharmacoeconomics. 2003;21:601-622.
4 . National Institute of Mental Health. Bipolar Disorder 2009. Available at: http://www.nimh.nih.gov/health/publications/bipolar-disorder/nimh-bipolar-adults.pdf. Accessed August 24, 2012.
For further information:
Contact: Emmanuelle Weiller, H. Lundbeck A/S, EMWE@lundbeck.com, +33680421831